All in favor say ‘eye’
Executive Summary
Bausch & Lomb's Optura (besifloxacin ophthalmic suspension) receives unanimous support Dec. 5 for treatment of bacterial conjunctivitis. Members of FDA's Dermatologic and Ophthalmic Drugs Advisory Committee added no hesitations or qualifications to their 9-0 vote that besifloxacin's benefits outweigh its risks, agreeing with FDA's conclusions that the sponsor conducted three adequate and well-controlled trials supporting the drug's efficacy
You may also be interested in...
Pfizer, Bausch & Lomb Team Up On Ophthalmology
U.S. co-promotion will combine sales forces to promote Pfizer’s Xalatan and Bausch & Lomb’s Alrex, Lotemex, Zylet and besifloxacin.
Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race
Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.
Novo Mulls What To Do With Wegovy Windfall
The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.